

Inferred resolution through herd immunity of first COVID-19 wave in Manaus, Brazilian Amazon

Thomas A. A. Prowse^{1,¶}, T. Purcell^{2,¶}, Djane C. Baía-da-Silva³, V. Sampaio⁴, Wuelton
M. Monteiro⁵, James Wood⁶, I. Mueller^{7,8}, Jodie McVernon^{9,10,11}, Marcus V. G.
Lacerda^{12,#}, Joshua V. Ross^{1,#}

¹School of Mathematical Sciences, The University of Adelaide, Adelaide, South Australia 5005, Australia

²Victorian Infectious Diseases Reference Laboratory Epidemiology Unit at The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, Victoria 3000, Australia

³Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil

⁴Fundação de Vigilância em Saúde; Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil

⁵Universidade do Estado do Amazonas; Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil

⁶School of Population Health, UNSW Sydney, Australia

⁷Population Health and Immunity Division, Walter + Eliza Hall Institute, Parkville, Victoria, Australia

⁸Department of Medical Biology, FMDHS, University of Melbourne, Parkville; Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France

⁹Victorian Infectious Diseases Reference Laboratory Epidemiology Unit at The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, Victoria 3000, Australia

¹⁰Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne

¹¹Infection and Immunity Theme, Murdoch Childrens Research Institute, Parkville.

¹²Instituto Leônidas & Maria Deane, Fiocruz; Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil

#Joshua V. Ross, School of Mathematical Sciences, The University of Adelaide, Adelaide, South Australia 5005, Australia

¶ equal first authors

equal last authors

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 **Abstract**

2 **Background**

3 As in many other settings, peak excess mortality preceded the officially reported ‘first wave’
4 peak of the COVID-19 epidemic in Manaus, Brazil, reflecting delayed case recognition and
5 limited initial access to diagnostic testing.

6 **Methods and Findings**

7 To avoid early information bias, we used detailed age and gender stratified death certificate
8 and hospitalisation data to evaluate the epidemic’s trajectory and infer the cause of its decline
9 using a stochastic model. Our results are consistent with heterogenous transmission reducing
10 from mid-April 2020 due to the development of herd immunity. Relative to a baseline model
11 that assumed homogenous mixing across Manaus, a model that permitted a self-isolated
12 population fraction reduced the population-wide attack rate required to drop the effective
13 reproduction number below one from 62 % to 47 %, and reduced the final attack rate from 86%
14 to 65%. In the latter scenario, a substantial proportion of vulnerable, older individuals remained
15 susceptible to infection.

16 **Conclusions**

17 Our models indicate that the development of herd immunity amongst the mixing proportion of
18 the Manaus population had effectively halted the COVID-19 epidemic by late July 2020. Given
19 uncertainties regarding the distancing behaviours of population subgroups with different social
20 and economic characteristics, and the duration of sterilising or transmission-modifying
21 immunity in exposed individuals, we conclude that the potential for epidemic outbreaks

- 22 remains, but that future waves of infection are likely to be much less pronounced than that
- 23 already experienced.

24 **Introduction**

25 Globally, marked differences have been observed in morbidity and mortality due to SARS-
26 CoV-2 infection. This variability mostly reflects the extent and timeliness of spontaneous and
27 imposed changes in social mixing and the sensitivity of surveillance systems to detect cases
28 and deaths [1]. Many countries that successfully constrained the initial epidemic through
29 distancing measures are now experiencing second waves in still-susceptible populations [2].

30 Estimates of R_0 for SARS-CoV-2 in the range 2 to 6 [3, 4] suggest that population immunity
31 of approximately 50-80% is required to achieve herd protection. However, heterogeneous
32 behaviour, infectivity and immunity within subpopulations could plausibly decrease this
33 threshold to 10-20% [5]. Controversy remains regarding the extent of population exposure
34 required to achieve such constraint [6].

35 Comparison of population attack rates to inform this question is made challenging by
36 imperfect case ascertainment, compounded by limited diagnostics and overwhelmed health
37 systems, particularly in high incidence settings. Assessment of epidemic activity therefore
38 requires the use of less biased metrics than confirmed case reports. Excess mortality is an
39 objective measure which, with cause-of-death certification, can be used as an indicator of
40 direct and indirect COVID-19 associated mortality [7]. With hospitalisations data, it can
41 inform retrospective estimation of cumulative cases and deaths [8].

42 Brazil experienced a severe first wave of COVID-19 disease, with mass mortality reported in
43 many states, mainly in the north where seasonality of respiratory infections contributed to
44 higher vulnerability. A socialized health system provided free and global access to tertiary care
45 hospitals, but inequalities might explain different mortality rates in the population [9]. In
46 Manaus, the highly urbanised capital of Amazonas state, the first case of COVID-19 was

47 reported on 13 March 2020 [10]. By 11 August 2020, 37,597 cases and 2,051 deaths were
48 reported [11].

49 However, burial and death records indicate far higher mortality than official reports, suggesting
50 late recognition of importation and underreporting. Previous studies have assumed that the first
51 wave in Manaus was significantly mitigated by non-pharmaceutical interventions (NPIs) [12].
52 While these restrictions may have partly constrained early transmission, local reports indicate
53 that implementation was highly variable [13]. Moreover, a possible role for immunity is
54 suggested by the observation of declining cases and deaths over a period in which restrictions
55 were officially eased.

56 We use death certificate and hospitalisation records to parameterise an epidemiological model
57 of the COVID-19 epidemic in Manaus. The model allows inference of age- and gender-
58 stratified infection-fatality ratios to explore evidence for development of herd immunity as a
59 driver of local epidemic resolution, with implications for the ongoing risk posed by SARS-
60 CoV-2 to this population.

61 **Methods**

62 **Excess mortality and reported causes**

63 Death certificate data from January 2015 to July 2020 were sourced from the Brazilian
64 Ministry of Health Mortality Information System (SIM). Information on age, gender, and
65 cause and date-of-death was recorded. Cause of death was reported using the World Health
66 Organization's (WHO) International Classification of Diseases 10th revision (ICD-10). The
67 2010 population census and the 2019 municipal population estimates were accessed from the
68 Brazilian Institute of Geography and Statistics (IBGE). This project was approved by the

69 *Fundação de Medicina Tropical Dr Heitor Vieira Dourado* Ethics Review Board (Approval
70 4.033.218).

71 Background mortality was calculated by averaging the number of deaths observed per week,
72 commencing on January 1 each year, for the previous 5 years (2015-2019). Background
73 mortality was further stratified by gender and into 5-year age bands, culminating at 75+. For
74 each subgroup, we subtracted this five-year average from deaths observed for the period
75 between March 19 and June 24 of 2020 to determine excess deaths. This period was selected
76 as excess mortality was first observed in the week beginning on March 19 and the data returned
77 to baseline background mortality in the week beginning on June 25.

78 The age and gender structure reported in the 2010 population census was used to estimate the
79 2019 population size for each age and gender class. Population estimates were aggregated into
80 5-year age bands. The 5-year population estimates for 2019 were used to determine excess
81 mortality, as a proportion of the population.

82 The ICD-10 codes assigned to each death certificate were aggregated into 7 categories: diseases
83 of the respiratory system (J00-J99), circulatory system (I00-I99), endocrine system (E00-E99),
84 unattended (R98) and unknown cause of death (R99), coronavirus infection (B34.2) and all
85 remaining codes were categorised as ‘other’. All analyses were performed using R software.

86 **Hospitalisation data**

87 Hospitalisation data for patients admitted to all hospitals (private and public) in Manaus from
88 January 2020 to July 2020 was accessed from the Influenza Surveillance Information System
89 (SIVEP-Gripe). Data entry in this system is compulsory by law. A deidentified line list
90 included patient demographics, comorbidities, clinical symptoms, investigations, clinical
91 management and outcome data.

92 Daily admissions to both hospital and intensive care units (ICU) were aggregated each week
93 in 2020 and stratified into 3 age bands (0-29, 30-64 and 65+). For each week, the proportion
94 of hospital and ICU admissions within each age group was determined. Between April and
95 July, the proportional distribution of hospital and ICU admissions across the three categories
96 remained fairly stable, with no evidence of rationing of service access on the basis of age.

97 **Epidemiological model**

98 We developed a stochastic, discrete-time, susceptible-infected-recovered epidemiological
99 model for Manaus which we calibrated using daily time-series data from the death-certificate
100 and hospitalisation records. The model assumed an initial population size equal to that of
101 Manaus in 2019 (2,182,761), which was split into $N=36$ age/gender groups based on
102 proportions reported in the 2010 census (i.e., 5-year age classes up to an age of 75 years, and
103 then a pooled age class for all individuals aged 75 years and over). To allow inference on the
104 background mortality rate in each age/gender group, the model was initiated on January 1,
105 2020, approximately two months prior to the introduction of COVID-19. The model was
106 terminated after $n=202$ days on July 20, 2020, to ensure complete reporting of both death
107 certificates and hospitalisations over the modelled period. The model detailed below was fitted
108 within a Bayesian framework using *JAGS* (v. 4.3.0) software [14] and a mixture of informative
109 and uninformative priors (for full details of the model code, including details of all prior
110 distributions, see Supplementary Appendix S1).

111 **COVID-19 introduction and virus transmission.** We initialised the model by allowing
112 importation of COVID-19 cases into Manaus over the week beginning March 5, 2020 (one
113 week before the first reported case), and inferred an importation model such that the number
114 of introduced cases into each group in each day of this first week arose from a Poisson process

115 with a common mean inferred from the data. To model community transmission, we inferred
116 a reproduction number on day t that was modified by an index of human mobility

$$117 \quad R_t = e^{(\log(R_0) + aX_t)} \quad (1)$$

118 where R_0 is the basic reproduction number, X_t is the mobility covariate and a is the inferred
119 coefficient. We derived the time-series X_t by first averaging daily data for five separate indices
120 of community mobility (available as the mobility change relative to baseline for
121 retail/recreation, grocery/pharmacy, parks, transit stations and workplaces, accessed from
122 www.google.com/covid19/mobility), and then smoothed the series with a 7-day moving-
123 average smoother. We then assumed the effective reproduction number $R_{eff(i,j,t)}$ in group i due
124 to mixing with group j on day t is

$$125 \quad R_{eff(i,j,t)} = R_t Q_i M_{i,j} S_{i,t} \quad (2)$$

126 where Q_i is the susceptibility of group i to infection, $M_{i,j}$ is the rate of mixing between the two
127 groups, and $S_{i,t}$ is the time-varying proportion of susceptible (previously uninfected)
128 individuals remaining in the focal group. Based on previous studies [15, 16], we used prior
129 means for the susceptibilities of 0-15, 15-60, and 60+ year old age classes of 0.5, 1.0, and 1.3,
130 respectively.

131 Mixing between groups was governed by an age-structured mixing matrix reported previously
132 for Brazil [17], which we corrected to be symmetrical (by averaging the upper and lower
133 triangles), scaled to a mean of $1/N$, and applied equally to both genders. The expected number
134 of new cases in each group each day was then calculated as

$$135 \quad C_{i,t} = \sum_{j=1}^N R_{eff(i,j,t)} (c_{j,1:(t-1)} \cdot g_{(t-1):1}) \quad (3)$$

136 where $c_{j,1:(t-1)}$ is the case-history vector for group j and $g_{(t-1):1}$ is the portion of the generation
137 interval distribution relevant to those cases. We used the same generation interval distribution
138 as Mellan et al. [12] which concentrated >99% of an individual's infectivity within the first 3
139 weeks of infection (median generation interval=5 days).

140 To account for heterogeneity in transmission, we assumed the offspring distribution in group i
141 due to mixing with infectious individuals from group j on day t was governed by a negative
142 binomial distribution with mean equal to $C_{i,t}$ and variance equal to $C_{i,t}(1 + C_{i,t}/\phi_{i,t})$, where

143
$$\phi_{i,t} = kC_{i,t}/R_t \quad (4)$$

144 and k is the overdispersion parameter, such that smaller values of k represent greater
145 transmission heterogeneity (i.e., the more transmission is due to a small number of people,
146 including by so-called "superspreaders"). Given no previous study has documented strong
147 evidence of different susceptibility between genders, we first generated the expected number
148 of new cases in each age class (regardless of gender), and then assumed gender-specific cases
149 arose from a binomial distribution with probability equal to the proportion of the total
150 susceptible individuals for that age class attributable to each gender.

151 **Background and COVID-induced mortality.** We developed a model for the expected
152 number of deaths per day which was comprised of three components. First, we modelled the
153 background (pre-COVID-19) death rate d_i estimated separately for each group. Second,
154 available data on the time from symptom onset to death for confirmed COVID-19 cases (from
155 the Manaus hospitalisation records) were used to infer a 4-parameter (y_0, u_{\min}, u_0, b) mortality
156 distribution (m) as a function of the time x since symptom onset ($x \in \{-5, \dots, N-5\}$) of the form

157
$$m_{x+a} = \frac{y_0 e^{u_{\min}(x+a) + ((u_0 - u_{\min})/b)(1 - e^{-b(x+a)})}}{\sum_{j=1}^N m_j} \quad (5)$$

158 where a is the average time from infection to symptoms, which was fixed at 5 days [3, 18, 19].
159 Finally, we modelled the infection-fatality ratio in each group i (IFR_i) as a log-linear function
160 of age and gender, with prior distributions on this components' parameters based on a recent
161 meta-analysis of COVID-19-induced mortality [20]. Together, these components yielded the
162 following model for the expected number of deaths

$$163 \quad D_{i,t} = d_i + IFR_i \sum_{j=1}^N (c_{j,1:(t-1)} \cdot m_{(t-1):1}) \quad (6)$$

164 and the observed number of deaths each day was assumed to arise from a Poisson distribution
165 with mean equal to $D_{i,t}$.

166 **Hospitalisations due to COVID-19.** Hospitalisations were modelled in a similar way to
167 COVID-induced deaths, in that available data on the time from symptom onset to
168 hospitalisation were used to infer a 4-parameter hospitalisation distribution (h) of the same
169 functional form as that used for the mortality distribution above. We modelled the infection-
170 hospitalisation ratio in each group i (IHR_i) as a logistic function of age and gender. Daily
171 hospitalisations were assumed to arise from a Poisson distribution with mean equal to

$$172 \quad H_{i,t} = IHR_i \sum_{j=1}^N (c_{j,1:(t-1)} \cdot h_{(t-1):1}) \quad (7)$$

173 **Model scenarios.** Given no data were available on whether some portion of the Manaus
174 population has been self-isolating since March 2020, we initially fitted a 'baseline' model to
175 death-certificate and hospitalisation data which assumed homogeneous age-structured mixing
176 across the entire Manaus population. We compared these model outcomes to those from a
177 second model that permitted a self-quarantined proportion (P) of the population which could
178 not be exposed to the SARS-CoV-2 virus. Communication with local experts including authors
179 on this paper suggested that more wealthy residents of Manaus had been able to greatly reduce

180 social interactions during the first epidemic wave and avoid exposure to the virus. We reviewed
181 detailed socio-demographic data on Manaus [21], but were not able to source quantitative
182 estimates of the relevant population fraction. However, we considered that this would not
183 exceed the upper 2 income quintiles (40%) of the population but was likely to be greater than
184 the wealthiest 10%, and accordingly, chose a non-informative uniform (0.1,0.4) prior on this
185 population fraction.

186 **Herd-immunity threshold.** To estimate the herd-immunity threshold for the baseline model
187 scenario, we calculated the discrete-time next-generation matrix from the mixing matrix and
188 posterior means for R_0 and age-structured susceptibilities Q . We then calculated the
189 deterministic reproduction number (R) as the dominant eigenvalue of this matrix, and
190 estimated the herd-immunity threshold as $1 - 1/R$. For each model, we also derived another
191 estimate of this threshold that incorporated the inferred age/sex distribution of cases, by
192 calculating the population-wide attack rate at which the expected number of offspring per case
193 (R_{eff} multiplied by the normalised case-infectivity vector) fell below one.

194 **Results**

195 We calculated 3,457 excess deaths in Manaus, Brazil, between 19 March and 24 June 2020
196 (Supplementary Table 1) representing 0.16% of the city's population. Males 30 years and over
197 experienced greater excess mortality than females; individuals aged 75 years or more
198 accounted for 39% of the excess (Fig 1A). During this period, 7% of the 75+ male population
199 in Manaus died (Fig 1B). COVID-19 deaths were first reported from 26 March and increased
200 weekly thereafter in keeping with improved access to diagnostics and/or increasing prevalence
201 (Fig 2), comprising 53% of the total excess. Other reported causes of death included respiratory
202 diseases, unattended and unknown causes of mortality, cardiovascular, endocrine and cancer-

203 related mortality, the majority of which were compatible [22] with a clinical diagnosis of
204 COVID-19 or are known comorbidities associated with severe outcomes (Fig 2).

205 Stochastic transmission models captured the observed peak in excess deaths in late April,
206 including age and gender variation (Fig 3, Figs S1 and S2). The models also captured
207 synchronous peaks in hospitalisations (Fig 3, Figs S3 and S4), although model fit to these data
208 was poorer, potentially reflecting delayed recognition of COVID-19 cases and/or capacity
209 exceedance during the epidemic peak.

210 Despite their different assumptions about the proportion of the Manaus population at risk, the
211 two model scenarios yielded equivalent fits to the data (Fig 3A, B). The baseline model
212 estimated heterogenous transmission ($k=0.065$ [0.047, 0.093], mean [95 % credible intervals]),
213 a mean time-to-death of 13 days (Fig S5), and inferred a population-wide attack rate of 85.7
214 [84.6, 86.7]% by 20 July. Attack rates were lowest in younger age classes (Fig 3A,i), reflecting
215 lower susceptibility assumed for people under 15 years.

216 Infection fatality rate (IFR) estimates for the baseline model ranged from almost zero for both
217 genders aged 30-35 years, to 3.0 [2.8, 3.3]% and 7.4 [6.8, 8.0]% for females and males over 75
218 years, respectively (Fig 4). At a population level, reduced mobility resulted in variable R_t , while
219 the expected offspring per case fell below one after April 12 (Fig S6), when the estimated
220 attack rate was 61.8 [61.1, 62.6]%. The traditional estimate of the herd-immunity threshold
221 based on the discrete-time next-generation matrix calculated from this model was 71.8 %.

222 Outcomes were similar for the second model which estimated $Q = 24.5$ [23.0, 25.1]% of the
223 Manaus population was effectively removed from the susceptible pool. Relative to the baseline
224 model, this second model estimated the expected offspring per case fell below one after April

225 11 when the attack rate was 46.8 [46.0, 47.7]%, and reduced the final attack rate to 65.0 [63.7,
226 65.6]%.
227

227 **Discussion**

228 Early time-series modelling of the COVID-19 epidemic in Brazilian states up to 6 May 2020
229 used an unstructured model informed by state-level mobility indicators and reported deaths
230 [12]. The model inferred population attack rates ranging from 0.13% to 10.6%, for Minas
231 Gerais and Amazonas, respectively, and predicted ongoing epidemic growth throughout May.
232 Other modelled R_0 estimates based on reported COVID-19 cases from Amazonas state have
233 similarly anticipated continued growth in cases through the month of June [13]. These models
234 could neither explain nor accurately forecast observations of epidemic decline in Manaus.

235 Our analysis of excess deaths and hospitalisations in Manaus identifies rapid epidemic growth
236 from late March, peaking in late April, with a return to baseline mortality in early June. These
237 age- and gender-stratified models inferred heterogeneous transmission consistent with previous
238 studies of SARS-CoV-1 [23] and SARS-CoV-2 [24]. In the baseline model, the expected
239 offspring per case fell below one at a population-wide attack rate of 61.8%. This model
240 suggests the herd-immunity threshold was exceeded in Manaus, with resulting attack rates
241 inferred to be 86% by July 20 2020. In contrast, the attack rate stabilised at 65 % for the second
242 model which estimated the risk of infection applied to *c.* 75% of the population only. Both
243 models suggest that, primarily due to herd protection, the expected number of offspring per
244 cases fell below one in early April.

245 Although both models estimated declining SARS-CoV-2 transmission over time due to herd
246 immunity, their implications for the possibility of subsequent waves are qualitatively different.
247 Although there are currently no data to support the assertion that some fraction of the Manaus

248 population self-isolated, we consider the second model is likely more realistic because: (1) the
249 estimated infection-fatality ratios are higher than reported from high-income countries [25]
250 which we anticipate to be plausible; and (2) a population attack rate of 65% is more consistent
251 with recent estimates based on a Manaus blood bank serosurvey [26] which reported the largest
252 increase in seropositivity over the month of April.

253 We focus on Manaus as the epicentre of the COVID-19 epidemic in Amazonas, avoiding
254 conflation of case numbers in this dense city of more than 2 million people with slower
255 growing rural outbreaks across the state [6]. Given known information bias associated with
256 limited early testing capacity, we used excess deaths and hospitalisations as the most
257 objective indicators of epidemic activity presently available. Detailed cause-of-death data
258 support the hypothesis that the majority of excess mortality over this time was COVID-19
259 related.

260 An important caveat is that estimated attack rates accumulate all infections and are agnostic to
261 the presence or degree of symptoms. Severity of the clinical course of COVID-19 is associated
262 with magnitude and persistence of the host immune response [27]. In consequence, our
263 estimates of ‘exposure’ cannot be directly related to predicted antibody seroprevalence at the
264 end of the first wave [28]. It is reasonably anticipated that population immunity will wane over
265 time, requiring robust memory responses [29] to prevent reinfection or modify the clinical
266 course [30].

267 Our findings support emerging evidence that population heterogeneity of SARS-CoV-2
268 transmission, attributable to a range of biological and sociological factors, reduces the herd
269 immunity threshold [24, 31, 32]. Reduction of superspreading events through constraints on
270 mixing group sizes is concordant with genomic studies showing successive extinction of
271 imported strains under the influence of social and mobility restrictions [33].

272 While future infection clusters and outbreaks remain possible in Manaus due to unexposed
273 subgroups, population-level immunity will likely constrain widespread transmission unless
274 immunity wanes. As in other settings, underlying vulnerability of older age groups may be
275 further exacerbated over time by reduced health seeking behaviours of individuals with pre-
276 existing and new medical conditions [34]. Social measures should be informed by
277 understanding of key enablers of superspreading and amplification, awareness of at-risk
278 populations and tailored to context depending on population experience of the first wave.

279 Excess mortality data are not sufficiently timely to support real-time decision making, but in
280 areas with limited testing may be a more reliable indicator of past epidemic activity than
281 confirmed cases. To accurately support response to and assess the impact of the COVID-19
282 and other public health emergencies, improved access to diagnostics, and strengthening of
283 reporting systems are needed in low- and middle-income settings. Cross-sectional and
284 longitudinal seroprevalence studies are essential to understand markers and maintenance of
285 immunity to inform prediction of long-term epidemiologic trends and bridging to likely vaccine
286 impacts [26, 35].

287 REFERENCES

- 288 1. Dye C, Cheng R, Dagpunar J, Williams B. The scale and dynamics of COVID-19
289 epidemics across Europe. 2020.
- 290 2. Klein A. Australia looks to be finally beating its second wave of coronavirus
291 [https://www.newscientist.com/article/2252690-australia-looks-to-be-finally-beating-its-](https://www.newscientist.com/article/2252690-australia-looks-to-be-finally-beating-its-second-wave-of-coronavirus2020)
292 [second-wave-of-coronavirus2020](https://www.newscientist.com/article/2252690-australia-looks-to-be-finally-beating-its-second-wave-of-coronavirus2020).
- 293 3. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in
294 Wuhan, China, of Novel Coronavirus–Infected Pneumonia. 2020;382(13):1199-207. doi:
295 10.1056/NEJMoa2001316. PubMed PMID: 31995857.

- 296 4. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High
297 Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2.
298 Emerging Infectious Disease journal. 2020;26(7):1470. doi: 10.3201/eid2607.200282.
- 299 5. Aguas R, Corder RM, King JG, Goncalves G, Ferreira MU, M. Gomes MG. Herd
300 immunity thresholds for SARS-CoV-2 estimated from unfolding epidemics.
301 2020:2020.07.23.20160762. doi: 10.1101/2020.07.23.20160762 %J medRxiv.
- 302 6. Ferrante L, Steinmetz WA, Almeida ACL, Leão J, Vassão RC, Tupinambás U, et al.
303 Brazil's policies condemn Amazonia to a second wave of COVID-19. Nature Medicine.
304 2020. doi: 10.1038/s41591-020-1026-x.
- 305 7. Felix-Cardoso J, Vasconcelos H, Rodrigues P, Cruz-Correia R. Excess mortality during
306 COVID-19 in five European countries and a critique of mortality analysis data.
307 2020:2020.04.28.20083147. doi: 10.1101/2020.04.28.20083147 %J medRxiv.
- 308 8. Thompson RN, Hollingsworth TD, Isham V, Arribas-Bel D, Ashby B, Britton T, et al.
309 Key questions for modelling COVID-19 exit strategies. Proc Biol Sci.
310 2020;287(1932):20201405. Epub 2020/08/13. doi: 10.1098/rspb.2020.1405. PubMed
311 PMID: 32781946.
- 312 9. Croda J, Oliveira WKd, Frutuoso RL, Mandetta LH, Baia-da-Silva DC, Brito-Sousa JD,
313 et al. COVID-19 in Brazil: advantages of a socialized unified health system and
314 preparation to contain cases %J Revista da Sociedade Brasileira de Medicina Tropical.
315 2020;53.
- 316 10. Amazonas Health Surveillance Foundation FVS. Amazonas confirms 1st case of Covid-
317 19 and authorities guarantee that the assistance network is prepared for assistance 2020
318 [29 June 2020]. Available from: http://www.fvs.am.gov.br/en/noticias_view_en/3740

- 319 11. Amazonas Health Surveillance Foundation FVS. COVID-19 Monitoring Panel. Manaus,
320 Brazil 2020 [11 August 2020]. Available from:
321 http://www.fvs.am.gov.br/indicadorSalaSituacao_view/60/2.
- 322 12. Mellan TA, Hoeltgebaum HH, Mishra S. Estimating COVID-19 cases and reproduction
323 number in Brazil. Imperial College London, 2020.
- 324 13. de Souza WM, Buss LF, Candido DDS, Carrera JP, Li S, Zarebski AE, et al.
325 Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil. *Nat*
326 *Hum Behav.* 2020;4(8):856-65. Epub 2020/08/02. doi: 10.1038/s41562-020-0928-4.
327 PubMed PMID: 32737472.
- 328 14. Plummer M. JAGS: A Program for Analysis of Bayesian Graphical Models using Gibbs
329 Sampling. 3rd International Workshop on Distributed Statistical Computing (DSC 2003);
330 Vienna, Austria. 2003;124.
- 331 15. Zhang J, Litvinova M, Liang Y, Wang Y, Wang W, Zhao S, et al. Changes in contact
332 patterns shape the dynamics of the COVID-19 outbreak in China. 2020;368(6498):1481-
333 6. doi: 10.1126/science.abb8001 %J Science.
- 334 16. Davies NG, Klepac P, Liu Y, Prem K, Jit M, Pearson CAB, et al. Age-dependent effects
335 in the transmission and control of COVID-19 epidemics. *Nature Medicine.* 2020. doi:
336 10.1038/s41591-020-0962-9.
- 337 17. Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using
338 contact surveys and demographic data. *PLOS Comput Biol.* 2017;13(9):e1005697. doi:
339 10.1371/journal.pcbi.1005697.
- 340 18. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation
341 Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed
342 Cases: Estimation and Application. *Annals of Internal Medicine.* 2020;172(9):577-82.
343 doi: 10.7326/M20-0504.

- 344 19. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral
345 shedding and transmissibility of COVID-19. *Nature Medicine*. 2020;26(5):672-5. doi:
346 10.1038/s41591-020-0869-5.
- 347 20. Levin AT, Meyerowitz-Katz G, Owusu-Boaitey N, Cochran KB, Walsh SP. Assessing
348 the age specificity of infection fatality rates for COVID-19: systematic review, meta-
349 analysis, and public policy implications. 2020:2020.07.23.20160895. doi:
350 10.1101/2020.07.23.20160895 %J medRxiv.
- 351 21. United Nations Development Programme. Atlas of human development in Brazil
352 (http://www.atlasbrasil.org.br/2013/en/perfil_m/manaus_am/, accessed 16/09/2020).
353 16/09/2020. Report No.
- 354 22. Excess deaths associated with COVID-19. Provisional death counts for coronavirus
355 disease (COVID-19). National Center for Health Statistics, Centers for Disease Control
356 and Prevention [updated August 26, 2020; 1st September 2020]. Available from:
357 https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm.
- 358 23. Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the effect of
359 individual variation on disease emergence. *Nature*. 2005;438(7066):355-9. doi:
360 10.1038/nature04153.
- 361 24. Endo A, Abbott S, Kucharski A, Funk S. Estimating the overdispersion in
362 COVID-19 transmission using outbreak sizes outside China [version 3; peer review: 2
363 approved]. 2020;5(67). doi: 10.12688/wellcomeopenres.15842.3.
- 364 25. Levin A, Meyerowitz-Katz G, Owusu-Boaitey N, Cochran K, Walsh S. Assessing the
365 age specificity of infection fatality rates for COVID-19: systematic review, meta-
366 analysis, and public policy implications. 2020.
- 367 26. Buss L, Prete CA, Jr., Abraham C, Mendrone A, Salomon T, de Almeida-Neto C, et al.
368 COVID-19 herd immunity in the Brazilian Amazon. 2020.


- 369 27. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological
370 assessment of asymptomatic SARS-CoV-2 infections. *Nat Med*. 2020;26(8):1200-4.
371 Epub 2020/06/20. doi: 10.1038/s41591-020-0965-6. PubMed PMID: 32555424.
- 372 28. Hallal P, Hartwig F, Horta B, Victora G, Silveira M, Struchiner C, et al. Remarkable
373 variability in SARS-CoV-2 antibodies across Brazilian regions: nationwide serological
374 survey in 27 states. 2020.
- 375 29. Rodda L, Netland J, Shehata L, Pruner K, Morawski P, Thouvenel C, et al. Functional
376 SARS-CoV-2 specific immune memory persists after mild COVID-19. 2020.
- 377 30. Ledford H. COVID-19 reinfection: three questions scientists are asking. *Nature*.
378 2020;585:168-9.
- 379 31. Britton T, Ball F, Trapman P. A mathematical model reveals the influence of population
380 heterogeneity on herd immunity to SARS-CoV-2. 2020;369(6505):846-9. doi:
381 10.1126/science.abc6810 %J Science.
- 382 32. Wang Y, Teunis P. Strongly Heterogeneous Transmission of COVID-19 in Mainland
383 China: Local and Regional Variation. 2020;7(329). doi: 10.3389/fmed.2020.00329.
- 384 33. Pybus OG, Rambaut A, du Plessis L, Zarebski AE, Kraemer MUG, Raghwani J, et al.
385 Preliminary analysis of SARS-CoV-2 importation and establishment of UK transmission
386 lineages. 2020.
- 387 34. Kluge HHP, Wickramasinghe K, Rippin HL, Mendes R, Peters DH, Kontsevaya A, et al.
388 Prevention and control of non-communicable diseases in the COVID-19 response.
389 *Lancet*. 2020;395(10238):1678-80. Epub 2020/05/14. doi: 10.1016/S0140-
390 6736(20)31067-9. PubMed PMID: 32401713; PubMed Central PMCID:
391 PMC7211494.

392 35. Koopmans M, Haagmans B. Assessing the extent of SARS-CoV-2 circulation through
393 serological studies. Nat Med. 2020;26(8):1171-2. Epub 2020/07/29. doi:
394 10.1038/s41591-020-1018-x. PubMed PMID: 32719488.

395

396


397 **Fig 1. Excess mortality in Manaus during the COVID-19 epidemic.** (a) Total excess
398 mortality by age and gender for the period between March 19 and June 24 of 2020. Excess
399 mortality is the 2020 weekly observed mortality less the expected mortality summed for the
400 period between March 19 and June 24 of 2020 for each subgroup. (b) Excess mortality for the
401 period between March 19 and June 24 of 2020 divided by the estimated 2019 subgroup
402 populations to obtain population proportions.



403


404

405 **Fig 2. Weekly mortality in Manaus by reported cause of death during the COVID-19**
406 **epidemic.** Observed weekly mortality for the period between January 01 and July 22 of 2020
407 aggregated by major ICD-10 categories of attributed causes of death.




408

409 **Fig 3. Integrated model fits by gender and model.** Results are pooled at the level of three
410 aggregated age classes: (A) 0-30 years; (B) 30-60 years; and (C) 60+ years. For each age class,
411 panels (i) and (ii) show the fit of the model (lines) to the reported number of deaths and
412 hospitalisations per day (points), while panel (iii) shows inferred attack rates. Note that lines
413 showing the model fits overlap in panels (i) and (ii), and attack rates for males and females
414 overlap in panel (iii).



415

416 **Fig 4. Estimated infection-fatality and infection-hospitalisation ratios.** Model-based
417 estimates (mean \pm 95 % credible intervals) of age- and gender-structured (A) infection-fatality
418 ratios (IFRs) and (B) infection-hospitalisation ratios (IHRs). Note that in panel (A), IFRs were
419 fixed at zero for all age classes below 30 years.



420

421

422

423

424

425

426

Supplementary Material to:

427

Inferred resolution through herd immunity of first

428

COVID-19 wave in Manaus, Brazilian Amazon

429

Thomas A. A. Prowse, T. Purcell, Djane C. Baía-da-Silva, V. Sampaio, Wuelton M.

430


Monteiro, James Wood, I. Mueller, Jodie McVernon, Marcus V. G. Lacerda, Joshua V. Ross

431 **Table S1.** Excess mortality in Manaus, Amazonas, during the COVID-19 epidemic (here
432 defined as the period between March 19 and June 24, 2020).

Age	Females			Males			Total	
	Expected mortality	Observed mortality	Excess mortality	Expected mortality	Observed mortality	Excess mortality	Total Excess mortality	Excess mortality (%)
0-5	84.5	65	-19.5	109.6	83	-26.6	-46.1	-23.7
5-10.	13.2	3	-10.2	19.3	10	-9.3	-19.5	-60
10-15.	13.5	6	-7.5	19.3	11	-8.3	-15.8	-48.2
15-20	26.1	14	-12.1	64.3	45	-19.3	-31.4	-34.7
20-25	24.1	22	-2.1	116.4	78	-38.4	-40.5	-28.8
25-30	26.7	30	3.3	92.2	81	-11.2	-7.9	-6.6
30-35	30	35	5	81.2	88	6.8	11.8	10.6
35-40	38.3	53	14.7	79	118	39	53.7	45.8
40-45	44.6	88	43.5	72.4	154	81.7	125.1	107
45-50	53.3	110	56.7	79.8	184	104.2	160.9	120.8
50-55	59.2	114	54.8	99	225	126	180.8	114.3
55-60	73.2	180	106.8	121.2	310	188.8	295.6	152.1
60-65	95.6	215	119.4	139.2	436	296.8	416.2	177.3
65-70	101.6	283	181.4	148.6	510	361.4	542.8	216.9
70-75	110.2	276	165.8	143.6	456	312.4	478.2	188.4
75+	468.4	996	527.6	382.4	1208	825.6	1353.2	159.1
Total	1262.4	2490	1227.6	1767.5	3997	2229.5	3457.2	114.1

433

434




435


436 **Fig S1.** Baseline model fits to daily deaths data for all 32 age and gender classes. Shown are

437 the model-inferred expected death rate from all causes (lines) \pm 95% credible intervals

438 (ribbons), and the mortality data used for model fitting (points).




439
440 **Fig S2.** The fit of Model 2 to daily deaths data for all 32 age and gender classes. Shown are
441 the model-inferred expected death rate from all causes (lines) \pm 95% credible intervals
442 (ribbons), and the mortality data used for model fitting (points).




443

444 **Fig S3.** Baseline model fits to hospitalisations data for all 32 age and gender classes. Shown
445 are the model-inferred expected hospitalisation rate (lines) \pm 95% credible intervals (ribbons)
446 and the hospitalisations data used for model fitting (points).




447
448 **Fig S4.** The fit of Model 2 to hospitalisations data for all 32 age and gender classes. Shown
449 are the model-inferred expected hospitalisation rate (lines) \pm 95% credible intervals (ribbons)
450 and the hospitalisations data used for model fitting (points).



451

452 **Fig S5.** Estimates from the baseline model (mean \pm 95 % credible intervals) of the shape of
453 the (A) mortality distribution and (B) hospitalisation distribution, as a function of time since
454 infection. Vertical bars indicate empirical frequencies derived from hospitalisation records
455 for Manaus. In (A), the dashed line indicates the mortality distribution used by a previous
456 COVID-19 modelling study for the State of Amazonas, Brazil [12].



457

458 **Fig S6.** Estimates from the baseline model (mean \pm 95 % credible intervals) of: (A) the
459 impact of personal mobility on the time-varying reproduction number (R_t); and (B) the
460 population-level effective reproduction number (R_{eff}) over time, which here is calculated as
461 the sum of the products of all $R_{eff(i,j,t)}$ and the normalised case-infectivity vectors at each
462 time t . In the latter, R_{eff} rises initially as the case distribution converges on the stable
463 distribution, and $R_{eff} < 1$ indicates the switch to negative epidemic growth due to the
464 development of herd immunity.